Drug Profile
Research programme: Gram negative infection therapeutics - ContraFect/Rockefeller University
Alternative Names: Gram-negative lysins - Contrafect/Rockfeller University; Lysin GN123Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator ContraFect; Rockefeller University
- Class Antibacterials; Endolysins; Recombinant proteins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Gram-negative-infections in USA
- 03 May 2021 ContraFect has patent protection for lysins in treating Gram-negative infections in USA
- 14 Nov 2016 ContraFect and Rockefeller University agree to co-develop lysin therapeutics in USA for Gram-negative infections